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Abstract
Coronavirus disease (COVID)-19 outbreak was the first time experienced in Wuhan City, China, at the end of 
December 2019 which spreads rapidly in China and then worldwide approximately all countries of America, Europe, 
Australia, and Asia including Bangladesh. There are more than 1,039,135 mortalities and 35,207,771 people have 
been affected globally until October 4, 2020, and the figure is still increasing. The global information on the COVID-
19 case was collected from a reliable database (worldometers.info) and domestic information was taken from the 
government circulating websites and analyzed. Different steps have been taken to control the COVID-19 worldwide. 
Even with few resources, Bangladesh also has taken rigorous measures such as designed special hospitals, 
laboratories, quarantine facilities, social distance awareness campaigns, and lockdown to control the spreading of the 
virus. As Bangladesh is an overpopulated country and vast population lives under the poverty line, it was difficult to 
maintain a strict lockdown to curb the COVID-19. In this study, we have focused the government efforts to combat this 
deadly pneumonia and presented recent situations and challenges of Bangladesh. We compiled general treatments, 
COVID-19 specific treatments, and antiviral treatments should be prescribed in fighting COVID-19. We suggest 
certain nutritional elements and natural products which can boost up the immunity of individuals and protect from the 
infection of this virus. The review was undertaken to synopsis the recent conditions, challenges of Bangladesh arise 
after the COVID-19 pandemic and summarize certain possible intervention options for management of COVID-19.
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Introduction
Coronaviruses (CoVs) fits the subfamily 
Orthocoronavirinae, in the family of Coronaviridae, and 
the order of Nidovirales. There are four categories of 
CoV; alpha-CoV, beta-CoV, gamma-CoV, and delta-
CoV [1]. Mainly, CoVs cause enzootic infections in 
mammals and birds. In the past periods, they have shown 
their competence in infecting humans [2]. At present, a 
novel flu-like CoV (severe acute respiratory syndrome 
[SARS] -CoV-2) is related to the Middle East respiratory 
syndrome (MERS) and SARS that outbursts in 2002 
and 2012, respectively, was found at the end of 2019 
in Wuhan, Hubei Province of China [3], [4]. This CoV 
had >95% homology with bat CoV and >70% similarity 
with SARS-CoV [3]. Compared with SARS and MERS, 
this virus is highly infective and transmissible despite a 
low mortality rate [5]. Human-to-human transmission of 
this virus is confirmed [6]. It is important that though the 
number of new cases was comparatively condensing in 
China, exponentially increased in other countries such as 
Italy, Spain, America, South Korea, and Iran. Bangladesh 
had reported only 368,690 cases until October 4, 2020. 
Among them, 5348 patients have already died. Until 
October 4, 2020, around 35,207,771 cases of CoV and 
1,039,135 deaths have been reported in all over the 
world. Providentially, children have been intermittently 
pretentious with no deaths. The upcoming course of 
this virus is still unknown. In this review, we have tried to 
figure out a clear observation of Bangladesh’s cause of 
the CoV Disease (COVID)-19 pandemic. This includes 
monthly cases of COVID-19 infections around the 
county, mortalities, health service facilities, and lacking. 
We discuss the burdens which Bangladesh faces now 
such as economical and educational pressures. Finally, 
certain potential intervention options are discussed in 
Bangladesh perspective which might be beneficial for the 
world against COVID-19. The objectives of this review are 
to summarize the present condition, challenges, and focus 
on potential medication, including both modern treatments 
and traditional home therapies to control CoV.
Genetic Structure of SARS-COV-2
CoV encircled single-stranded positive-sense 
RNA viruses with a diameter of 60 nm–140 nm, which 
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containing spike-like projections on its surface that 
giving it a crown-like presence under the electron 
microscope. For this reason, its name is CoV [7]. They 
have a typical genome structure that belongs to the 
cluster of beta-CoVs. It is more than 82% identical 
to SARS-CoV [4], [8]. The SARS-CoV-2 virus uses 
angiotensin-converting enzyme 2 (ACE2) of the host 
cell, as a receptor-like SARS-CoV [9]. In general, this 
type of CoV recognizes the target cell’s equivalent 
receptor through the S-protein on its surface and enters 
into the cell for instigating the infection [8]. Wrapp et 
al. also showed by a structural model analysis that 
SARS-CoV-2 binds with ACE2 with the affinity above 
10 folds higher than SARS-CoV [10]. COVID-19 is 
high in occurrence, and the population is generally 
susceptible to SARS-Cov-2, which spread rapidly 
from a single Wuhan city to the entire country within 3 
days [8]. Infection of this virus occurs not only through 
large droplets formed from coughing and sneezing 
by symptomatic patients but also from asymptomatic 
people [11]. These droplets spread 1–2 m easily and 
can remain attached on surfaces. In advantageous 
conditions, the virus can remain live on surfaces for 
days but can be destroyed in less than one minute 
using disinfectants such as hydrogen peroxide, sodium 
hypochlorite, and so on [12]. Other human infection 
is assimilated either by inhalation of these droplets or 
touching the surfaces contaminated by them. The virus 
is also present in the patient’s stool and can pollute the 
water supply through aerosolization [3].
COVID-19 Pathophysiology
The genome of SARS-COV-2 is similar to 
a previously identified CoV strain that caused the 
SARS outbreak in 2003 [13]. Structurally, the SARS 
CoV has a well-defined composition comprising of 14 
binding residues that directly interact with the human 
ACE2 receptor. Among these amino acids, 8 are 
conserved in SARS-CoV-2 [14]. Although the precision 
pathophysiological mechanisms of SARS-CoV-2 are 
unknown, genomic similarities to SARS-CoV may assist 
to elucidate the resulting inflammatory response that 
could lead to the onset of severe pneumonia [14]. Until 
the laboratory trials initiated, the precise mechanism 
of SARS-CoV-2 remains hypothetical. All types of 
CoVs contain specific genes in ORF1 downstream 
regions that are responsible for encoding proteins for 
viral replication, nucleocapsid, and formation of spikes 
[15]. The glycoprotein spikes situated on the outer 
surface of CoVs are responsible for the attachment 
and entry of the virus to host cells (Figure 1). The 
receptor-binding domain (RBD) remain attached 
loosely among virus, so that, the virus may infect many 
hosts [16]. SARS-CoV-2 possesses the typical CoV 
structure with spike protein and also expressed other 
membrane proteins, polyproteins, and nucleoproteins 
[17]. The spike protein of SARS-CoV-2 comprises a 
3-D structure in the RBD region for maintaining the 
Van der Waals forces [18]. The 394 glutamine residue 
in the RBD region of SARS-CoV-2 can recognize by 
the critical lysine 31 residue on the ACE2 receptor [19]. 
The description of the entire pathogenicity mechanism 
of SARS-CoV-2 from attachment to replication is in 
Figure 1. ACE2 is a membrane-bound aminopeptidase 
that has an important contribution to the immune 
system and cardiovascular. ACE2, a receptor, engages 
in heart function and the development of diabetes 
mellitus and hypertension. ACE2 can be a functional 
receptor not only for SARS-CoV but also for SARS-
CoV-2 [20]. SARS-CoV-2 infection is activated by 
binding the virus’s spike protein to ACE2, which is 
highly articulated in the lungs and heart [20]. SARS-
CoV-2 mainly attacks alveolar epithelial cells, which 
outcomes in respiratory symptoms. Weather, ACE2 is 
an efficient receptor for SARS-CoV-2, the well-being 
and potential effects of anti-hypertension therapy with 
ACE inhibitors or angiotensin-receptor blockers in 
patients with COVID-19 should deliberate prudently. If 
patients with COVID-19 and hypertension are taking 
an ACE2 inhibitor or angiotensin-receptor blocker can 
be an antihypertensive drug. Patients with COVID-19 
are showing high cardiovascular symptoms. ACE2 is 
extensively expressed not only in the lungs but also 
in the cardiovascular system. Therefore, ACE2-related 
signaling pathways might also have a role in heart 
injury.
Figure 1: An outline of the life cycle of SARS-CoV-2 in the host cell; 
the life cycle of the virus starts when S protein attaches with cellular 
angiotensin-converting enzyme 2 (ACE2). After the ACE2 receptor 
binding, there happens a structural modification in the S protein which 
enables the viral envelope fusion with the cell membrane through a 
route called the endosomal pathway. Then, SARS-CoV-2 releases 
RNA into the host cell. Genomic RNA is translated into viral replicase 
polyproteins pp1a and 1ab, which are then cleaved into small 
products. The polymerase produces a series of subgenomic mRNAs 
by discontinuous transcription and finally translated into relevant viral 
proteins. Viral proteins and RNA are subsequently accumulated into 
virions in the Endoplasmic Reticulum and Golgi and then transported 
through vesicles and released out of the cell (ACE2: Angiotensin-
converting enzyme 2; ER: Endoplasmic reticulum; ERGIC: ER-Golgi 
intermediate compartment)
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Current Situation in Bangladesh
The first patient of COVID-19 identified in the 
country on 8th March. According to the Health Ministry of 
Bangladesh, there are almost 368,690 positive cases in 
the country and 5348 people have died until October 4, 
2020. The highest cases appeared in the Dhaka Division 
(142,741) followed by Chattogram (47,473), Khulna 
(21,936), Rajshahi (20,158), Sylhet (12,685), Rangpur 
(12,083), Barishal (8399), and Mymensingh (6471) have 
been confirmed (Figure 2). A total of 281,656 infected 
people have been recovered in Bangladesh to date. The 
mortality rate in Bangladesh is 1.45% and the recovery 
rate is 76.39% [21]. After identifying the first patient 
of COVID-19 in Bangladesh on 8th March, it is being 
dangerous day by day. Not only total cases but also total 
death number is increasing every day. Every month, the 
total cases and death rates became more than double 
until June and then slightly declined (Figure 3) [22].
Figure 2: Division-wise COVID-19 cases in Bangladesh
Bangladesh is a dense population country with 
inadequate resources. The testing or diagnostic facility is 
limited in Bangladesh. The pandemic has proven to be a 
big challenge in Bangladesh, as the infectious nature of 
the virus can rapidly infect a large number of people in 
any given time or place. Many poor people in Bangladesh 
are living in different slams; they use a single toilet and 
bathroom for a large number of people. As CoV is so 
contagious, so if any person from a slum will be corona 
positive, it will be so dangerous for that slum [23]. There 
has a large number (836,000) of Rohingya population 
residing in different camps [24]. Because of the fast 
infectious nature of the virus, the infection in one of 
the camps can be disastrous. Bangladesh is currently 
suffering from the availability of not only the testing kits but 
also testing labs that are essential for the detection of the 
virus. It is difficult to have social isolation in the densely 
packed camps, where several people are residing in a 
small space and have to rely on the collective effort for 
their collective survival. Any form of mass infection can 
be alarming for the rest of the countries.
In Bangladesh, millions of dollars’ worth of 
readymade garments products of many international 
apparel brands had withdrawn their buying orders 
from a huge number of companies. It has created a 
knock-on effect on the Bangladeshi economy. For this 
reason, many small companies are already closed, and 
many people became unemployed and their livelihood 
condition is becoming worsen. The top companies are 
not recruiting now and reducing their employees. If this 
situation would run for more time, those people may 
involve in various crimes and it will be another challenge 
for the whole country.
Like most of the countries, Bangladesh also 
closed their educational institutes for more than 7 
months to control the COVID-19. This is why nearly 
40 million students are now out of institutions. This 
condition will continue until the epidemic returns to a 
normal stage [25]. The government is trying to use online 
or satellite television platforms to deliver education 
during the pandemic, but it is not enough to meet the 
complementary levels. Since the price of internet 
packages is higher, and almost 90% of students do not 
have any large-screen devices which can help them 
more in online education. Approximately 75% of people 
were affected by the decrement of family earnings 
during the lockdown and also worried about the job of 
their family members [25]. Many peoples are becoming 
jobless; most of their monthly payments are decreasing. 
During the COVID-19, many private companies are 
giving <50% payment [26]. As a result, the ability to 
buy nutritious food for their family is declining day by 
day, which affects their children in various malnutrition 
diseases. As family income has been decreased, some 
of the students are forcing to join multiple risky jobs 
Figure 3: Monthly-wise COVID-19 outbreak in Bangladesh
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such as construction, garment-sector, driving bus, auto-
rickshaw, and many more. Parents are forcing their girls 
to marry at an early age [25]. However, there are several 
non-government organizations that provide free food and 
necessary things to street children for education. Due 
to the COVID-19 outbreak, their educational activities 
have been postponed that may affect their mental 
development and future growth. Dropped-out students 
can be involved in any illegal and criminal activities [27].
Facilitation by the Government of 
Bangladesh against COVID-19
The Government of Bangladesh has taken all 
necessary measures against the virus, to provide and 
ensure the responsibilities of the country. Since the 1st day 
when the first case was confirmed by IEDCR, Dhaka, all 
the services and measures were used with the extreme 
capabilities to ensure the safety of life in the region. The 
government affords COVID-19 extenuation strategies with 
their measures such as early case detection, tracing and 
tracking of contacts, social distancing, risk communication, 
quarantine, and isolation to avoid the spreading of 
COVID-19 [28]. The Government of Bangladesh has 
announced several packages to address the impact of 
CoV. Our prime minister announced several packages 
for supporting not only the various private export-oriented 
companies but also for the agricultural sectors so that 
after this outbreak, the country can overcome the situation 
as soon as possible. She declared a BDT 5000 crore 
(emergency) incentive package for paying the salaries 
and allowances of export-oriented industries’ workers 
and employees [28]. Relief is also ongoing for poor and 
middle-income people. The test center is also increased 
with time. Now testing is done in every division of the 
country. Even though our government is trying so hard 
to control the outbreak, general people are unwilling to 
follow the lockdown. Law enforcer agencies are working 
on maintaining the lockdown properly.
Hospitals for COVID-19 in Bangladesh
Being a populated country, Bangladesh is 
doing arrangements to fight against the COVID-19. 
Lots of measures have been taken by the government 
of Bangladesh to control the outbreak. Many hospitals 
are working in this scenario, to bring back life and 
fight against the deadly outbreak of COVID-19 in the 
country. In the capital territory of Dhaka, there were 
12 functional hospitals. In every division, at least one 
hospital is reserved for COVID-19 patients.
Isolation Beds Facilities for COVID-19 in 
Bangladesh
Isolation centers are the separation of ill or 
infected persons from others for preventing the spread of 
infection. The hospitals use isolation centers for COVID-
19 people to keep them safely care and provide a healthy 
environment to stay mentally and physically strong. 
According to the Directorate General of Health Services 
(DGHS), there are 7693 isolation beds in Bangladesh. 
Among them, 29% is in the Dhaka division, 11% 
Chattogram, 9% in Khulna, 4% in Sylhet, 15% Rajshahi, 
7% in Barishal, and 13% Mymensingh [29]. ICU is not 
so available in a developing country like Bangladesh. 
Although there are 190 ICU beds in Bangladesh, and this 
is not sufficient for a huge country’s people (Figure 4) [21].
Figure 4: Division-wise isolation facilities in Bangladesh
Division-wise Quarantine Facilities for 
COVID-19 in Bangladesh
The quarantines, being considered to restrain 
people’s activities who are not sick now but might have 
been contacted to an infectious agent, such as, COVID-
19 with the purpose of monitoring symptoms. The spaces 
use for quarantine of COVID-19 suspected people was 
widely distributed in divisions. Until September 2020, 
344,660 individuals were kept in home quarantine all 
over the country; out of them 48% (47,812) have been 
already safe and released [21]. At present, the number 
of people in home quarantine has been decreasing and 
the decrease rate of almost 60%.
Testing and Diagnostic Facilities in 
Bangladesh
Globally, PCR is used for the COVID-19 test, 
which is the gold standard method. Bangladesh’s 
government also recommends the PCR test for COVID-19 
diagnosis. At present, a total of 109 labs are conducting 
CoV tests, 63 are located in the capital Dhaka city, and 
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other 46 labs are situated in the different district outside 
Dhaka [28]. Samples are collected from the test seekers of 
these districts are being sent and tested at the facilities lab 
in nearby districts or in Dhaka [30]. People also can give 
samples by contacting the lab authorities. In Bangladesh, 
currently, no rapid testing method is government 
approved, for example, antigen-antibody testing method. 
The maximum testing number was around 20,000 
samples each day in June month and this is inadequate 
for an overpopulated (160 million) country. Clinicians and 
experts suggest vigorous testing for mass-people. Since 
the outbreak, the country has tested nearly 1,989,664 CoV 
samples [31]. Government assures that new testing labs 
will be set up soon across the country with expert opinion.
Social Distancing Maintaining is Tough in 
Many Areas of Bangladesh
In starting, Bangladesh could not execute any 
strict restriction, and thousands of people were out on 
the roads, particularly in Dhaka, which is a megacity 
having 46 thousand people per square kilometer [32]. It 
seems that social distancing is really tough while taking 
public travel and living in the purlieus. In the context 
of enormously populated and lower-middle-income 
countries like Bangladesh, the implementation of social 
distancing which is recommended by the WHO seems 
to sound fancy but unreasonable. Over 1.1 million 
purlieu dwellers are living in the capital of Bangladesh, 
Dhaka [33]. Most children and parents have never 
gone to school and are living in an extremely close 
environment, scarcely aware of the threat from CoV. 
The household income of slum dwellers in Dhaka is 
around $100 per month and they use more than 70% 
of their incomes on food and housing [34]. Even a 
small pack (400-mL) hand soap, which costs around 
BDT 80 Taka, is hard for them to buy. Besides, every 
10–16 families have access to only a single bathroom 
and toilet, where there is lacking water supply and poor 
hygienic conditions [34], [35]. Along with slum dwellers, 
there are over one million Rohingya refugees are living 
in Bangladesh, most of them are living in close quarters 
in refugee camps where the sanitization facilities are 
not so good [36]. Fear of COVID-19 is already gearing 
up among those people in these camps. Instantaneous 
implementation of social distancing is practically 
impossible in a populated country like Bangladesh.
Clinical Characteristics of Sars-Cov-2 
Infection
COVID-19 makes an acute viral infection 
in humans within 3 days incubation period [37]. The 
presenting features of COVID-19 prominent in adults. 
The clinical features of infection are varied, ranging 
from an asymptomatic to acute respiratory distress 
syndrome (ARDS). Sometimes it also shows multi-
organ dysfunction [3]. Fever (87.9%), cough (67.7%), 
and fatigue (38.1%), whereas diarrhea (3.7%) and 
rarely vomiting (5.0%) are the most common indication 
of this virus infection [38]. Sometimes patients also 
experience headaches, myalgia, sore throat, and 
breathlessness [3]. Most patients had some degree 
of dyspnea because the onset time of symptoms to 
the development of ARDS was only 29% [39]. Hence, 
severe heart damage and secondary infection might 
happen for patients [40]. There are already some 
pieces of indication that COVID-19 also can cause 
damage to other tissues and organs instead of the lung. 
In a study, researchers reported that 36.4% of COVID-
19 patients had neurological manifestations [41]. 
Furthermore, there are already some indications of 
ocular surface infection in patients with COVID-19 
and SARS-CoV-2 [42]. Some COVID-19 patients have 
arrhythmia, acute heart injury, impaired renal function, 
and abnormal liver function (50.7%). A case report of the 
pathological manifestations of a patient with pneumonia 
showed modest microvesicular steatosis in liver tissue 
[43]. Normally the radiographical features of COVID-19 
were similar to community-acquired pneumonia caused 
by other organisms [44]. A recent study stated that most 
of the patients (90%) had bilateral chest computed 
tomography (CT) findings. The compassion of chest 
CT suggests that COVID-19 was 97% combining 
clinical symptoms and laboratory tests with chest CT 
imaging features could expedite the early diagnosis 
of COVID-19 pneumonia. Laboratory examination 
revealed that 82.1% of patients were lymphopenia 
and 36.2% of patients were thrombocytopenia. Most 
of the patients had normal leukocytes, but leukopenia 
observed in 33.7% of patients [8]. Most of the COVID-
19 patients confirmed dominant levels of C-reactive 
protein, creatinine kinase, and lactate dehydrogenase. 
The minority of patients showed abnormal myocardial 
enzyme spectrum, higher transaminase, or elevated 
serum creatinine [8]. In addition, lower levels of CD4+T 
and CD8+T, higher levels of interleukin (IL)-6 and IL-10, 
were present in COVID-19 patients [45].
Potential Treatment of SARS-COV-2
Antiviral Western medicine treatment
At present, COVID-19 patient’s treatments 
are mainly symptomatic. It has been reported that 
Remdesivir, an antiviral drug, can be used as a potential 
agent against a wide array of RNA viruses. Holshue et 
al. got decent results for the first time using Remdesivir 
against COVID-19 [46]. Meanwhile, analysts likewise 
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found that Chloroquine contains a safe regulating action 
on COVID-19 patients, which can viably hinder this 
infection [8]. Clinical preliminaries likewise demonstrated 
that Chloroquine ends up being working for COVID-19 
patients [47]. A small indole derivative molecule (Arbidol) 
found to block viral fusion against influenza A, B, and 
hepatitis C viruses [48] and also inveterate having an 
antiviral effect on SARS-CoV in cell experiment [49], 
so it might be a choice for COVID-19 treatment. Apart 
from the above, neuraminidase inhibitors, remdesivir, 
lopinavir/ritonavir, nucleoside analogs, and peptide 
EK1 could also be the choices of antiviral drugs against 
COVID-19 [50]. Baricitinib might decrease the process 
of both virus invasion and inflammation. It can be a 
potential treatment against COVID-19 [7].
Chinese medicine treatment
Chinese medicines are also being used for the 
treatment of SARS-CoV-2 infection. Numerous traditional 
Chinese medicine prescriptions are also published by 
local governments and medicinal institutions. Novel CoV, 
pneumonia, diagnosis, and treatment plan encouraged 
clearing lung and detoxification decoction in the clinical 
treatment [8]. CAS found that Shuanghuanglian oral 
liquid can inhibit SARS-CoV-2. Previous studies have 
proved that chlorogenic acid, baicalin, and forsythin in 
Shuanghuanglian oral liquid have definite inhibitory 
effects on a variety of viruses and bacteria [51]. These 
components played a therapeutic role by reducing the 
inflammatory response of the body. Lianhuaqingwen 
capsule has been proven to have a wide-spectrum effect 
on a series of influenza viruses, including H7N9, and 
could regulate the immune response of the virus [52].
Immunoenhancement therapy
Synthetic recombinant interferon α has proven 
to be an active treatment in clinical trials for the SARS 
virus [53]. Interferon is an effective inhibitor of the 
replication of MERS-CoV [54]. These findings suggested 
that we can use interferon for treating COVID-19 patients. 
Moreover, Thymosin alpha-1 (Ta1) can be a promoter 
for an immune system of SARS patients, meritoriously 
controlling the spread of COVID-19 disease [55]. 
Immunoglobulin, intravenous, and Ta1 may also be 
considered as therapeutics for COVID-19 disease.
Convalescent plasma therapy
Convalescent plasma therapy is a promising 
treatment that could be an effective way to assuage the 
course of disease for severely infected patients when 
no specific drugs and vaccines are sufficient [56]. It is 
more effective than severe doses of hormonal shock 
in patients with severe SARS, reducing mortality, 
and shortening days to stay hospital [57]. From the 
immunology perspective, most of the patients who 
recovered from COVID-19 would produce specific 
antibodies against the SARS-CoV-2 in their blood 
and serum. Those antibodies can be used to prevent 
reinfection. At the same time, those types of antibodies 
can limit the reproduction of the virus in the acute 
phase of infection and help to clear the virus, which is 
satisfactory to the rapid recovery of the disease.
Auxiliary blood purification treatment
According to the latest study, the main target 
to attack for novel CoV could be the kidney [58]. Most 
of the severe patients who are positive with novel CoV 
might agonize from a cytokine storm. Damage of the 
immune system can occur not only by the imbalance of 
pro-inflammatory but also by anti-inflammatory factors. 
Therefore, blood purification technology can be used for 
eliminating inflammatory factors, removing cytokine storm, 
adjusting electrolyte imbalance, and maintaining acid-base 
balance [59]. In summary, the drug treatment for COVID-
19, mainly founded on four types of antiviral Western 
medicine, Chinese medicine, immunoenhancement 
therapy, and viral-specific plasma globulin.
Nutritional interventions
As no exact treatment is available for this virus, 
there needs an urgent alternative method to improve 
our immune system. Some vitamins can protect us from 
this virus by improving body immunity. Vitamin A could 
be a promising option not only for the treatment of CoV 
but also for the prevention of lung infection. Vitamin A 
and retinoid can block measles duplication, which is an 
up-regulating element of the innate immune response, 
making them rebellious to fruitful infection during 
subsequent rounds of viral replication [60]. Vitamin 
B plays an indispensable role in the body’s immune 
function. Hence, it should be complemented to the virus-
infected patients for improving their immune system [4]. 
Vitamin C also augments immune functions and guards 
against CoV [61]. A few analysts suggested that Vitamin 
C may hold the weakness of the infection of the lower 
respiratory tract under specific circumstances [62]. The 
COVID-19 essentially causes contamination in the lower 
respiratory tract, so we can say Vitamin C could be one 
of the effective treatments for COVID-19. Vitamin D 
likewise invigorates the advancement of insusceptible 
cells [4]. Vitamin D could fill in as another helpful open 
door for treating the novel virus. Studies found that long-
chain PUFAs are significant intermediaries of adaptive 
immune responses and inflammation [63]. Therefore, 
Omega-3, including protectin D1, served as a novel 
antiviral drug that could be painstaking for one of the 
probable interventions of this virus. In addition, the 
combination of zinc at low concentrations and pyrithione 
can inhibit the replication of SARS-CoV [64].
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Antiviral role of natural products and their 
compounds
Right now, exact treatments are accessible for 
COVID-19 yet, explicit immunizations or medications 
are not in the markets, and even though trials are 
ongoing  65]. There is developing proof of the antiviral 
capability of herbal compounds and medicinal plant 
extracts [66]. These compounds are bioactive elements 
and show antiviral properties, efficacy standards, and 
safety in various reports. Modern pharmacologists 
already revealed different pharmacological bioactive 
compounds. Curcumin is the bioactive ingredient of 
turmeric, which is the best example of phytochemicals 
with a multi-functional mode of action [67], [68], [69]. 
In trials, curcumin shows a positive effect, and it can 
change the structure of the surface protein in viruses, 
hindering the entry of virus and their replication. Besides, 
curcumin affects membrane proteins by modulating the 
characteristics of the host lipid bilayer [70]. In molecular 
docking, it was proved that curcumin can bind to the 
target receptors, including SARS-CoV-2 protease, spike 
glycoprotein-RBD, and PD-ACE2 [71]. Onion and garlic 
are common sources that are known to have antiviral 
properties [72]. Notably, onion and garlic are rich homes 
of organosulfur compounds. Organosulfur compounds 
such as quercetin and allicin are associated with shame 
of viral disease [73]. Phytochemicals present in these 
plants have been functional to obstruct the development 
of protein and hereditary material in the infection 
[74], [75], [76]. Onion contains quercetin and kaempferol 
as main flavanols. These compounds have been found 
to affect the growth of many viruses [77]. Experiments 
have proved that garlic extract can minimize influenza A 
and B viral infections and strong inhibitory effects against 
the multiplication of the Infectious Bronchitis Virus (IBV), 
which affect the poultry industry [78], [79]. Similarly, ginger 
is a common spice and a widely used medicinal plant.
Ginger contains an important antiviral source 
of compound [80]. Neem (Azadirachta indica) is a 
medicinal plant and its parts such as leaves, seeds, 
flowers, barks, and routes are widely using in various 
diseases. Methanolic extract of neem leaves exhibited 
antiviral activity against herpes simplex virus (HSV) type 
1 infections by inhibiting HSV-1 glycoprotein mediated 
viral fusion [81]. Nimbolide is an active constituent 
of the Neem tree explored as a pharmacological 
modulator in treating various diseases. Tumor necrosis 
factor (TNF)-α is a pleiotropic cytokine involved in 
the activation of different signaling cascades and this 
cytokine might be playing a role in respiratory failure 
associated with COVID-19 mediated pneumonia. 
Nimbolide is found to be a TNF-α inhibitor and also 
suppresses the nuclear translocation of p65 NF-κB and 
HDAC-3 and inhibited the cytokine storm observed in 
ARDS experimental model [82]. Thus, it might show 
beneficial effects in SARS-CoV-2 infections by direct 
antiviral activity or indirect supportive therapy by 
controlling the inflammatory cytokine storm. This natural 
product may have clinical significance in inflammation 
associated with viral diseases. The other natural product 
Withaferin A is isolated from Ashwagandha (Withania 
somnifera) and widely used to treat various diseases 
like COVID 19. It has shown the antiviral activity against 
HSV-1 and 2, which may show plausible effects against 
COVID-19 [83].
CRISPR-Cas technique
Genome editing (CRISPR) could use for the 
treatment of this CoV, but this technique can only edit or 
target DNA [84]. Whether a new RNA-targeting CRISPR 
systems design is possible, it will be conceivable to 
treat this virus. In an outstanding new resource for the 
scientific community published in Nature Biotechnology, 
researchers in the lab at the New York Genome Center 
and New York University have developed a new kind 
of CRISPR screen technology to target RNA. They 
categorized the CRISPR enzyme named Cas13 that 
can targets RNA instead of DNA [85].
Potential Treatment in Bangladesh
Although the vaccine is the ultimate solution for 
COVID-19 management, it is not possible to get on time. 
Drug repurposing has become a promising approach 
for reducing the timelines of new drug development, 
cost, and making the treatment strategy easy [86]. At 
the initial stage of covid-19 infection and before starting 
community transmission in the country, Bangladesh 
government has given the approval to use certain 
potential antiviral drugs in fighting the CoV. These drugs 
are remdesivir [46], [87] and favipiravir [88] which have 
efficacy against viruses. Anti-parasitic medicine named 
ivermectin was also trialed on COVID-19 patients 
between 40 and 65 years olds. Bangladesh-based 
International Centre for Diarrhoeal Disease Research 
(ICCDR’B) has conducted the safety and efficacy of 
anti-parasitic medicine ivermectin in combination with 
antibiotic doxycycline or ivermectin alone. They found 
that initially the combination showed efficacy and cured 
all the COVID-19 patients who were administered with 
the drugs [89]. Hydroxychloroquine is a debatable 
drug for CoV and was trialed on COVID-19 patients. 
An observational study that was trialed in Bangladesh 
showed a combination of hydroxychloroquine and 
antibiotic azithromycin can reduce the mortality 
rate. The patients were given standard of care and 
administration of hydroxychloroquine and azithromycin. 
According to this finding, out of a total of 33 patients, 
1 patient died at days 4 after admission, and the rest 
patients recovered [90].
Conventional or traditional home remedies are 
also playing a vital role alongside modern treatment to 
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combat this virus and boosting the immunity of patients. 
Natural products such as spices in Bangladesh such 
as ginger, garlic, onion, clove contain phytochemicals, 
and bioactive compounds have antiviral activity against 
many viruses. Garlic, turmeric, ginger, cinnamon, black 
pepper, and honey were reported to be used in Pakistan 
as home remedies against COVID-19 [91]. Leaf extract 
of holy basil, black cumin seeds, juice of lemon, and 
sliced rhizomes of ginger was supplemented with 
slightly hot water to COVID-19 patients and found a 
positive effect [92] in Bangladesh. Holy basil is very 
popular as a medicinal plant and the antiviral activity 
of this plant has been reviewed [93]. Lemon contains 
Vitamin-C and enhances body immunity. Although Citrus 
limon was reportedly showed antiviral activity against 
different viruses, this food item should be taken to boost 
up immune system [94]. Tea is a popular hot drink in 
Bangladesh and East Asia. About 65 biomolecules of 
tea plants have been evaluated by bioinformatics tools 
(molecular docking) for their binding affinities to the 
main protease (Mpro) of the SARS-CoV-2 virus, which 
is considered the main target for the development 
of antiviral drugs [95]. Drinking tea alone or together 
with spices may protect from COVID-19 by improving 
defense mechanism. In this case, natural products and 
their home remedies could be an alternative option 
indirectly to improve immunity and protection from CoV 
in Bangladesh and worldwide.
Conclusion and Future Prospects
The current scenario of Bangladesh is not 
satisfactory because daily cases are more than a 
thousand still now. Bangladesh is a much-populated 
country that requires more facilitation. Bangladesh 
is a lower-middle-income country where the financial 
position is not better as compared to China, the USA, 
UK, and Russia to combat with COVID-19 outbreak. 
The number of quarantine and hospital facilities is 
not fulfilling as required. If these medical facilities can 
be improved, it would not be difficult to control the 
transmission of CoVs and the treatment of patients. At 
present, the testing facilities are much lower than the 
required target. The testing facilities could augment by 
5-10 folds. Bangladesh needs more screening facilities 
for the arrivals as well as for the departures.
We should take the right steps to control the 
situation worst such as staying at homes as much as 
possible, maintain lockdown and social distancing, 
use sanitizers, facemask, and PPE when necessary. 
Moreover, people should uptake Vitamin-C and dietary 
supplements to increase immunity boosting. We hope 
that Bangladesh will overtake the COVID-19.
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